Materiały źródłowe

• #1 RSV Vaccine VIS | Vaccines & Immunizations | CDC

  https://www.cdc.gov/vaccines/hcp/current-vis/rsv.html

  RSV vaccine can prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV). RSV is a common respiratory virus that usually causes mild, cold-like symptoms. […] RSV infections can be dangerous for certain adults. Adults at highest risk for severe RSV disease include older adults, especially those with chronic heart or lung disease, a weakened immune system, certain other chronic medical conditions, or who live in nursing homes. […] CDC recommends a one-time-dose of RSV vaccine for everyone 75 years and older and for adults 60 through 74 years of age who are at increased risk of severe RSV disease. Adults 60 through 74 years old who are at increased risk include those with chronic heart or lung disease, a weakened immune system, or certain other chronic medical conditions, and those who are residents of nursing homes. […] RSV vaccine may be given at the same time as other vaccines.

• #2 RSV (respiratory syncytial virus) vaccine – what you need to know: MedlinePlus Medical EncyclopediaLock

  https://medlineplus.gov/ency/article/007797.htm

  RSV vaccine can prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV). RSV is a common respiratory virus that usually causes mild, cold-like symptoms. […] Adults at highest risk for severe RSV disease include older adults, especially those with chronic heart or lung disease, a weakened immune system, certain other chronic medical conditions, or who live in nursing homes. […] CDC recommends a one-time-dose of RSV vaccine for everyone 75 years and older and for adults 60 through 74 years of age who are at increased risk of severe RSV disease. Adults 60 through 74 years old who are at increased risk include those with chronic heart or lung disease, a weakened immune system, or certain other chronic medical conditions, and those who are residents of nursing homes.

• #3 What to know about RSV, RSV vaccine – Mayo Clinic Health System

  https://www.mayoclinichealthsystem.org/hometown-health/featured-topic/what-parents-should-know-about-rsv

  RSV can be serious for infants and older adults, however. […] The Food and Drug Administration (FDA) has approved a seasonal vaccine to protect infants, pregnant people and older adults from RSV. […] To prevent severe RSV disease in infants, pregnant people can receive the vaccine during 32 to 36 weeks gestation. The baby receives protection from RSV complications for up to three months after birth. […] Immunization is recommended for infants under 8 months old who are not protected by a maternal RSV vaccination between 32 and 36 weeks of gestation during the current pregnancy and at least two weeks before birth. […] Active vaccines are approved for adults. Vaccines from multiple manufacturers are available for adults 75 and older or those 60 to 74 at risk for severe RSV disease. […] Healthcare professionals recommend vaccination during late summer or fall before RSV spreads in the community. […] Talk with your healthcare team regarding questions about when and where you or your infant may be able to receive the RSV vaccine.

• #4 RSV Vaccine Guidance for Older Adults | RSV | CDC

  https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/older-adults.html

  CDC recommends a single dose of RSV vaccine for older adults to help prevent serious RSV infection and hospitalization. […] Eligible adults can get an RSV vaccine at any time, but the best time to vaccinate patients is in late summer and early fall before RSV usually starts to spread in the community. […] The RSV vaccine is not currently an annual vaccine. People who have already received one dose (including last year) have completed their vaccination and should not receive another dose at this time. […] Eligible adults who have not previously received RSV vaccination may be vaccinated at any time of year, but vaccination will have the most benefit if administered in late summer or early fall, just before the RSV season. […] Currently, CDC recommends only a single dose of RSV vaccine for all adults ages 75 and older and for adults ages 6074 with increased risk of severe RSV disease.

• #5 Vaccines for Older Adults | RSV | CDC

  https://www.cdc.gov/rsv/vaccines/older-adults.html

  CDC recommends everyone ages 75 and older get an RSV vaccine. […] CDC recommends adults ages 60-74 who are at increased risk of severe RSV disease get an RSV vaccine. […] The RSV vaccine is not currently an annual vaccine. If you have received an RSV vaccine already (including last year), you should not get another RSV vaccine at this time. […] The RSV vaccine is given as a single dose. […] CDC recommends an RSV vaccine for all adults ages 75 years and older and for adults ages 60-74 years who are at increased risk of severe RSV. […] Conditions that increase your risk for severe illness include: Living in a nursing home. […] The RSV vaccine is not currently an annual vaccine. Protection from an RSV vaccine lasts more than one year. […] If you have a moderate or severe illness, you should wait until you recover before receiving an RSV vaccine.

• #6 Vaccines for Older Adults | RSV | CDC

  https://www.cdc.gov/rsv/vaccines/older-adults.html

  One dose of RSV vaccine provides protection against RSV disease in adults ages 60 years and older for at least two years. […] Based on the available data, ACIP and CDC continue to conclude that the benefits of RSV vaccination, in terms of preventable hospitalizations and deaths, outweigh the potential risk for GBS, among adults ages 75 years and older and among adults ages 60-74 years at increased risk of severe RSV disease.

• #7 RSV Vaccine Guidance for Older Adults | RSV | CDC

  https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/older-adults.html

  RSV vaccines can be coadministered with other adult vaccines during the same visit. […] GSK’s Arexvy, Modernas mResvia, or Pfizer’s Abrysvo should not be administered to a person with a history of severe allergic reaction, such as anaphylaxis, to any component of that vaccine. […] Adverse events after RSV vaccination should be reported to the Vaccine Adverse Event Reporting System (VAERS), even if it is not clear that the vaccine caused the adverse event. […] Encourage patients to sign-up for V-Safe, where they can share with CDC how they feel after getting an RSV vaccine.

• #8 RSV Recommendations and Guidance | Johns Hopkins | Bloomberg School of Public Health

  https://publichealth.jhu.edu/2024/rsv-recommendations-and-guidance

  Nirsevimab was found to be 90% effective in preventing infants from being hospitalized with RSV, according to the CDC. […] Three RSV vaccines are approved for use in the U.S. in adults ages 60 and older: GSK’s Arexvy, Pfizer’s Abrysvo, and Moderna’s mResvia. […] One dose of RSV vaccine provides protection against severe RSV disease in adults ages 60 years and older for up to two years, meaning people do not need to get a dose every RSV season. […] In clinical trials, Arexvy and Abrysvo were 78% effective in preventing severe RSV over a second year, according to the CDC, while mRESVIA showed 50% efficacy in preventing RSV after 18 months. […] RSV infections can be severe for babies and older adults, but these safe, effective vaccines can help prevent the worst outcomes.

• #9 Everything You Need to Know About the RSV Vaccine | ColumbiaDoctors

  https://www.columbiadoctors.org/news/everything-you-need-know-about-rsv-vaccine

  The very young and people older than 65 are at increased risk for RSV complications such as hospitalization, life-threatening pneumonia, and even death. […] There is not yet an approved RSV vaccine for people under age 60. […] Theres a maternal RSV vaccine and a monoclonal antibody for infants in development. In the meantime, if you are over 60 and live with a young child or pregnant person, getting the RSV vaccine can help protect them as well as yourself. […] According to the FDA, the Arexvy vaccine reduces the risk of developing RSV-associated LRTD (lower respiratory tract disease) by 82.6% and the risk of developing severe RSV-associated LRTD by 94.1%. The ABRYSVO vaccine reduces the risk of LRTD by 65.1% and severe LRTD by 88.9%. Those are significant statistics. […] Yes. Theres a new vaccine for infants and very young children. A monoclonal antibody immunization called nirsevimab was approved for infants younger than 8 months (who are experiencing their first RSV season this winter). Multiple studies show nirsevimab reduces hospitalizations and severe infections in infants. This vaccine is also recommended for children 8 to 19 months old who are at increased risk for severe RSV, such as those with chronic lung disease, those who are severely immunocompromised, or those living with severe cystic fibrosis.

• #10 RSV vaccines: Questions patients may have and how to answer | American Medical Association

  https://www.ama-assn.org/delivering-care/public-health/rsv-vaccines-questions-patients-may-have-and-how-answer

  Respiratory syncytial virus (RSV) season often starts in the fall and peaks in winter. RSV vaccines are available to help reduce risk for severe illness. […] In many parts of the country, the fall season of crisp, cool breezes and leaves changing colors is followed by a cold, snowy winter. But these seasons also bring with them respiratory syncytial virus (RSV), which can be serious for infants and older adults. And while there are RSV vaccines available, many require further guidance on what to do. […] The first vaccines for RSV were licensed by the Food and Drug Administration (FDA) in 2023 for older adults. There are now three RSV vaccines recommended for those 75 or older and for adults 60-74 years old who are at increased risk of severe RSV disease. […] RSV generally causes mild upper respiratory disease in healthy adults. But for adults 60 or older with certain underlying conditions or other risk factors, RSV can cause serious illness.

• #11 RSV vaccines: Questions patients may have and how to answer | American Medical Association

  https://www.ama-assn.org/delivering-care/public-health/rsv-vaccines-questions-patients-may-have-and-how-answer

  Additionally, those who are of advanced age, reside in nursing homes or other long-term care facilities and have underlying medical conditions can also benefit from RSV vaccination. […] Vaccination should occur before the onset of the fall and winter RSV season. […] Flu, COVID-19 and RSV vaccines may be given at the same visit. […] As with other vaccines, patients can expect some side effects from RSV vaccination. Some of the common side effects include fatigue, fever, headache, muscle or joint pain, nausea and diarrhea. The side effects are typically mild, says the CDC. […] Two immunization products are available for the prevention of severe RSV disease in infants. The maternal RSV vaccine (Pfizer’s Abrysvo) is given during weeks 32 through 36 of pregnancy during September through January in most of the U.S. Maternal antibodies protect the baby against RSV for approximately 6 months after birth.

• #12 Respiratory Syncytial Virus (RSV) Vaccine (Abrysvo®) – MotherToBaby

  https://mothertobaby.org/fact-sheets/respiratory-syncytial-virus-rsv-vaccine-abrysvo/

  This sheet is about exposure to the respiratory syncytial virus (RSV) vaccine in pregnancy and while breastfeeding. This information is based on available published literature. It should not take the place of medical care and advice from your healthcare provider. […] The RSV vaccine causes a person to make antibodies against RSV. When a woman gets the RSV vaccine at the recommended time during pregnancy (32-36 weeks), the antibodies she makes can pass to the developing baby. It takes about 2 weeks after getting the vaccine in pregnancy for antibodies to fully pass to the developing baby. These antibodies can help protect the baby from severe RSV infection for about 6 months after they are born. […] The only RSV vaccine approved for use in pregnancy in the United States (US) is called Abrysvo. The Centers for Disease Control and Prevention (CDC) recommend the Abrysvo RSV vaccine for women who are 32-36 weeks pregnant who have not received an RSV vaccine in a previous pregnancy. The RSV vaccine is only recommended for use during RSV season.

• #13 RSV Vaccine Guidance for Pregnant Women | RSV | CDC

  https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/pregnant-people.html

  To prevent severe RSV disease in infants, either maternal RSV vaccination or infant immunization with RSV monoclonal antibody is recommended. […] Pregnant women should get a single dose of the maternal RSV vaccine (Pfizers Abrysvo) during weeks 32 through 36 of pregnancy. […] CDC recommends a respiratory syncytial virus (RSV) vaccine for pregnant women to protect their babies from severe RSV disease. […] Pregnant women and their healthcare providers should discuss both maternal RSV vaccination and infant immunization with nirsevimab and consider patient preferences when deciding which product is best for their family. […] Providers should not administer maternal RSV vaccine outside of this seasonal timeframe unless the individual lives in an area where RSV circulation is less predictable and peak activity may vary.

• #14 RSV Vaccine Guidance for Pregnant Women | RSV | CDC

  https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/pregnant-people.html

  If an infant requires protection against severe RSV outside of the recommended seasonal administration for maternal RSV vaccination, healthcare providers should administer nirsevimab. […] CDC does not currently recommend maternal vaccination outside of this period in most of the U.S. because vaccinating a pregnant woman in February or March for an infant born in April or May will provide that infant limited protection during the RSV season. […] At this time, if a pregnant woman has already received a maternal RSV vaccine during any previous pregnancy, CDC does not recommend another dose of RSV vaccine during subsequent pregnancies. […] Maternal RSV vaccine can be administered during the same visit that a patient receives a Tdap, COVID-19, and/or influenza vaccine. […] Adverse events after maternal RSV vaccination should be reported to the Vaccine Adverse Event Reporting System (VAERS), even if it is not clear that the vaccine caused the adverse event.

• #15 Immunizations to Protect Infants | RSV | CDC

  https://www.cdc.gov/rsv/vaccines/protect-infants.html

  CDC recommends all babies be protected from severe RSV by one of two immunization options: A maternal RSV vaccine given to the mother during pregnancy or an RSV antibody given to your baby. Most babies do not need both. […] The maternal RSV vaccine (Pfizer’s Abrysvo) is given during weeks 32 through 36 of pregnancy. Maternal antibodies protect the baby against RSV for approximately 6 months after birth. […] If you have already received a maternal RSV vaccine during any previous pregnancy, CDC does not currently recommend you get another dose of RSV vaccine when you are pregnant again. Instead, your baby should receive nirsevimab. […] An RSV antibody (nirsevimab) is recommended for all babies younger than 8 months of age born to mothers who did not receive a maternal RSV vaccine (Pfizers Abrysvo) during pregnancy.

• #16 Respiratory Syncytial Virus (RSV) Vaccine (Abrysvo®) – MotherToBaby

  https://mothertobaby.org/fact-sheets/respiratory-syncytial-virus-rsv-vaccine-abrysvo/

  If a pregnant woman has already received an RSV vaccine during any previous pregnancy, she does not need to get an RSV vaccine again in her current pregnancy. Instead, she should talk to her healthcare provider about protecting her baby against RSV with nirsevimab (infant antibody). […] The Abrysvo RSV vaccine is only recommended for women who are pregnant (32-36 weeks) and for older adults. Studies have not been done on the RSV vaccine in women who are breastfeeding. The Advisory Committee on Immunization Practices (ACIP) and CDC state that subunit vaccines, like Abrysvo, pose no risk for women who are breastfeeding or their infants. Be sure to talk to your healthcare provider about all your breastfeeding questions.

• #17 Seven Things to Share with Your Patients About the Maternal RSV Vaccine | ACOG

  https://www.acog.org/programs/immunization-for-women/physician-tools/seven-things-to-share-with-patients-maternal-rsv-vaccine

  Health care professionals can also document the patients RSV vaccine status in the patients health record and the immunization information system and give documentation to the patient to communicate vaccination status. […] All infants are recommended to be protected from severe RSV disease by either the maternal RSV vaccine or nirsevimab for the RSV season. […] It is critically important that pregnant patients receive all recommended vaccines. Maternal RSV vaccine can be administered at the same time as other vaccines routinely recommended during pregnancy.

• #18 Respiratory Syncytial Virus (RSV) for Health Professionals – MN Dept. of Health

  https://www.health.state.mn.us/diseases/rsv/hcp.html

  To prevent severe RSV disease in infants, either maternal RSV vaccination or infant immunization with RSV monoclonal antibody is recommended. Most infants will not need both. […] Pfizer Abrysvo is the only RSV vaccine recommended during pregnancy. […] One dose should be given during weeks 32 through 36 of pregnancy, administered September through January (to protect infants born October through March). […] Nirsevimab (also known as Beyfortus) is a long-acting RSV monoclonal antibody recommended for infants/toddlers to prevent lower respiratory tract disease from RSV. […] The supply of Nirsevimab is projected to be adequate for the 2024-2025 season. […] These resources can be used to explain and encourage vaccination and immunization for pregnant people and/or infants as well as help them keep record of it.

• #19 RSV (Respiratory Syncytial Virus) | Vermont Department of Health

  https://www.healthvermont.gov/disease-control/immunizations/rsv-respiratory-syncytial-virus

  RSV vaccine is a single dose vaccine that can be given at any time throughout the year but the best time to get vaccinated is late summer through early fall. […] Talk to your health care provider to see if RSV immunization is recommended for you or your family. […] All babies are recommended to be protected from severe RSV by one of two immunization options. Most babies do not need both. […] The maternal RSV vaccine (Pfizers Abrysvo) is recommended if you are between 32 and 36 weeks pregnant during September through January in most of the U.S. […] An RSV antibody (nirsevimab) is recommended for all babies younger than 8 months of age born to mothers who did not receive a maternal RSV vaccine (Pfizers Abrysvo) during pregnancy. […] Nirsevimab is also recommended for a small group of young children 8 through 19 months of age who are at increased risk for severe RSV. […] Early real-world data show that nirsevimab was 80-90% effective in preventing babies from being hospitalized with RSV. It provides immediate protection against RSV and lasts at least 5 months.

• #20 Immunizations to Protect Infants | RSV | CDC

  https://www.cdc.gov/rsv/vaccines/protect-infants.html

  Nirsevimab is also recommended for a small group of young children 8 through 19 months of age who are at increased risk for severe RSV. […] RSV vaccine (Abrysvo) recommended during week 32-36 of pregnancy: September through January. Nirsevimab recommended for infant: October through March. […] As of October 1, 2023, most people with coverage from Medicaid and the Children’s Health Insurance Program (CHIP) will be guaranteed coverage of all vaccines recommended by the Advisory Committee on Immunization Practice at no cost to them.

• #21 Respiratory syncytial virus (RSV) | The Australian Immunisation Handbook

  https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/respiratory-syncytial-virus-rsv

  Nirsevimab is a long-acting RSV-specific monoclonal antibody that is recommended for infants who were born to women who did not receive RSV vaccine during pregnancy. […] Infants <3 months of age in their 1st RSV season have a greater risk of severe disease than older children in all categories. [...] The risk of hospitalisation from RSV for Aboriginal and Torres Strait Islander infants is around 2 times that of non-Indigenous infants of the same age. [...] Infants who live in regions where advanced care for severe RSV is not readily accessible may have greater benefit. [...] A single dose of RSV vaccine is recommended for adults aged ≥60 years with risk factors for severe RSV disease. [...] A single dose of nirsevimab is recommended before their 1st RSV season in young infants whose mothers did not receive RSV vaccine at least 2 weeks before delivery.

• #22 RSV: Nursing Diagnoses, Care Plans, Assessment & Interventions | NurseTogether

  https://www.nursetogether.com/respiratory-syncytial-virus-rsv-nursing-diagnosis-care-plan/

  RSV infection is a contagious condition that can spread by coughing, sneezing, or close contact. Nurses must educate patients and their families on preventing virus transmission. Nurses may care for sick, fragile patients in inpatient settings but can also instruct on strategies for protection of at-risk populations. […] Nursing interventions and care are essential for the patients recovery. In the following section, you will learn more about possible nursing interventions for a patient with respiratory syncytial virus. […] Supportive care remains the primary treatment for RSV, regardless of inpatient or outpatient treatment. […] Administer prophylaxis against RSV. Palivizumab, a monoclonal antibody, is an effective passive immunological prophylaxis for RSV. Administered monthly through RSV season, this medication can offer protection for premature infants or infants with heart, lung, or neuromuscular disorders.

• #23 RSV (Respiratory Syncytial Virus) Vaccine: MedlinePlus Drug InformationLock

  https://medlineplus.gov/druginfo/meds/a623035.html

  Side effects that have been reported with RSV vaccine include: Redness, swelling, pain, or tenderness where the shot is given, fever, feeling tired, headache, nausea, diarrhea, muscle or joint pain. […] Serious neurologic reactions, including Guillan-Barre Syndrome (GBS), have been reported very rarely after RSV vaccine in clinical trials. […] An allergic reaction could occur after the vaccinated person leaves the clinic. If you see signs of a severe allergic reaction (hives, swelling of the face and throat, difficulty breathing, a fast heartbeat, dizziness, or weakness), call 9-1-1 and get the person to the nearest hospital. […] The National Vaccine Injury Compensation Program (VICP) is a federal program that was created to compensate people who may have been injured by certain vaccines.

• #24 Respiratory Syncytial Virus (RSV) Vaccines | CDC Recommendations | AAFP

  https://www.aafp.org/family-physician/patient-care/prevention-wellness/immunizations-vaccines/disease-pop-immunization/rsv-vaccine.html

  Vaccine administration errors are known to occur and are routinely monitored through the Vaccine Adverse Event Reporting System. […] Healthcare providers should ensure use of the correct RSV prevention product in the correct population and take actions to prevent vaccine administration errors, including automating error prevention alerts in electronic health record systems, ensuring proper education and training on vaccine recommendations, paying close attention to labeling, and following proper storage and administration best practices. […] Healthcare providers are strongly encouraged to report vaccine administration errors to VAERS.

• #25 RSV (respiratory syncytial virus) vaccine – what you need to know: MedlinePlus Medical EncyclopediaLock

  https://medlineplus.gov/ency/article/007797.htm

  RSV vaccine may be given at the same time as other vaccines. […] In some cases, your health care provider may decide to postpone RSV vaccination until a future visit. […] People who are moderately or severely ill should usually wait until they recover before getting RSV vaccine. […] Serious neurologic conditions, including Guillain-Barré syndrome (GBS), have been reported after RSV vaccination in some older adults. At this time, an increased risk of GBS following RSV vaccine among persons aged 60 years and older cannot be confirmed or ruled out. […] Preterm birth and high blood pressure during pregnancy, including pre-eclampsia, have been reported among pregnant women who received RSV vaccine. It is unclear whether these events were caused by the vaccine. […] As with any medicine, there is a very remote chance of a vaccine causing a severe allergic reaction, other serious injury, or death.

• #26 RSV: Nursing Diagnoses, Care Plans, Assessment & Interventions | NurseTogether

  https://www.nursetogether.com/respiratory-syncytial-virus-rsv-nursing-diagnosis-care-plan/

  Nursing care plans help prioritize assessments and interventions for both short and long-term goals of care. […] Provide adequate respiratory support. If the patient has an underlying respiratory condition, such as asthma or COPD, ensure they receive appropriate respiratory support, such as bronchodilators or inhalers, to prevent respiratory distress and potential RSV infection.

• #27 Understanding the new RSV vaccination programme | Nursing in Practice

  https://www.nursinginpractice.com/clinical/vaccination-and-infection/understanding-the-new-rsv-vaccination-programme/

  Nurse consultant Linda Nazarko explains the new RSV vaccination programme and how nurses can support patients to understand the benefits of taking up the vaccine. […] The programme aims to protect infants and older adults, who are most at risk from severe disease from RSV infection. […] The UK vaccination programme is using the same RSV vaccine (Abrysvo; Pfizer) for older adults and pregnant women. […] The RSV vaccination programme aims to protect those who are most vulnerable to serious illness from RSV infection, namely infants and older adults. […] The two groups being offered RSV vaccination are: All pregnant women, in every pregnancy, from 28 weeks gestation (so their babies are protected from birth). […] Older people aged 75-79 years. The one-off vaccination should not usually be given at the same time as influenza or Covid vaccine in this group. […] The same RSV vaccine (Abryvso) is used for older adults and pregnant women. It is given as a single dose. […] It is hoped the programme will save lives and reduce long-term health effects following infection. The programme should also reduce pressure on primary and acute care.

• #28 Respiratory Syncytial Virus (RSV) Vaccines | CDC Recommendations | AAFP

  https://www.aafp.org/family-physician/patient-care/prevention-wellness/immunizations-vaccines/disease-pop-immunization/rsv-vaccine.html

  Many older adults may not know that they should get an RSV vaccine. Incorporating your patients’ vaccination needs into their regular visits whether for chronic disease management, wellness exams or acute care can help normalize getting vaccinated as part of comprehensive care. […] A strong, clear recommendation from a health care professional is the best predictor of whether a patient will get vaccinated. […] The AAFP endorses the following RSV vaccination recommendations from the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention: All adults 75 and older should receive a single dose of an RSV vaccine. Adults 60 to 74 who are at increased risk for severe RSV illness should receive a single dose of an RSV vaccine. […] The RSV vaccine is not currently an annual vaccine, so people who have previously received it do not need to get another dose.

• #29 Clinical Overview of RSV | RSV | CDC

  https://www.cdc.gov/rsv/hcp/clinical-overview/index.html

  CDC recommends a single dose of RSV vaccine to protect all adults ages 75 and older and adults ages 6074 who are at increased risk of severe RSV. […] To protect infants from severe RSV, CDC recommends an RSV vaccine for pregnant women (Pfizer’s Abrysvo) or a monoclonal antibody (nirsevimab) given to the baby. […] Nirsevimab is also recommended for a small group of young children ages 819 months before or entering their second RSV season. […] A recommendation from a healthcare provider is one of the most important factors that influences a patient’s choice to accept a new prevention product or vaccine. […] Health care providers caring for adults aged 6074 years residing in these communities may use clinical judgement, knowledge of local RSV epidemiology, and community incidence of RSV-associated hospitalization to recommend vaccination for a broader population in this age group.

• #30 Fresh appeal to older people and pregnant women to get RSV vaccine | Nursing in Practice

  https://www.nursinginpractice.com/clinical/respiratory/fresh-appeal-to-older-people-and-pregnant-women-to-get-rsv-vaccine/

  Around 1.3 million older people who are not yet vaccinated against respiratory syncytial virus (RSV) are being invited to book an appointment at their GP practice to have the jab. […] NHS England has today issued a fresh appeal to older people and pregnant women to take up the RSV vaccine offer warning that the virus is not just a winter illness. […] Pregnant women are also eligible for the vaccine from 28 weeks onwards and are being encouraged to speak to their maternity service or GP practice. […] General practice nurses in England, Wales and Northern Ireland began rolling out the RSV vaccination programme last September, with a programme in Scotland beginning last August. […] Steve Russell, NHS national director for vaccinations and screening, said: RSV is not just a winter illness. We see cases increase in winter, but it can occur all year round and can make older people seriously ill, so it is vital everyone eligible gets vaccinated. […] He added that vaccines for RSV, Covid-19 and flu also protect against other respiratory infections, meaning it is especially important to have each vaccine when offered.

• #31 RSV Vaccine: A Breakthrough in Protecting Infants and Expectant Mothers | NETEC

  https://netec.org/2024/12/20/rsv-vaccine-a-breakthrough-in-protecting-infants-and-expectant-mothers/

  Despite clinical trials that show the benefits of the maternal RSV vaccine outweigh the risks, vaccine hesitancy remains a barrier to widespread immunization. […] Clinical studies have demonstrated that the RSV vaccine is safe for administration during pregnancy, with no significant increase in adverse outcomes such as preterm birth. […] Clinical trials have demonstrated that the RSV vaccine is safe for pregnant women and reduced the risk of infant hospitalization for RSV by 68%. […] Educating patients about the prevalence and severity of RSV underscores the vaccine’s importance. […] When discussing the RSV vaccine with patients, take a clear, empathetic, and personalized approach. […] Highlight that the vaccine underwent rigorous testing in pregnant women and has been endorsed by major health organizations like the American Association of Pediatricians and the American College of Obstetricians and Gynecologists. […] The RSV vaccine is a significant breakthrough, offering a safe and effective way to protect newborns during their most vulnerable months.

• #32 Everything You Need to Know About the RSV Vaccine | ColumbiaDoctors

  https://www.columbiadoctors.org/news/everything-you-need-know-about-rsv-vaccine

  The United States Food and Drug Administration (FDA) has approved two RSV vaccines for adults 60 and older. The CDC recommends that adults age 65 and older get an RSV vaccine. Adults 60 to 64 can get a prescription after talking to their doctor or other health care provider. The CDC recommends that adults 60 and older receive an RSV vaccine after talking to their doctor or other health care provider. […] Shared clinical decision-making takes into account a persons individual characteristics, values, and preferences, says Beecham Robinson. Its how she works with every patient she sees. In terms of RSV, she says, healthcare providers will also consider each patients risk of severe RSV disease to decide whether RSV vaccination is right for them. […] A severe RSV infection can lead to serious health problems like pneumonia and bronchiolitis, an inflammation in the lungs. People who have a chronic medical condition, especially heart disease, chronic lung disease, or diabetes, are particularly at risk. And most likely to have an RSV infection land them in the hospital.

• #33 RSV Vaccination in LTC | CCO

  https://clinicaloptions.com/activities/infectious-disease/rsv-vaccination-in-ltc/67132/content

  This lack of awareness was a significant barrier that needed to be overcome. […] The RSV vaccine did not receive the same level of media attention as did the COVID-19 vaccines, and I saw this as both a challenge and an opportunity. […] First, I explain the nature of RSV infection, its potential severity, and its potential outcomes, such as pneumonia, hospitalization, and death. […] Second, I address the safety and efficacy of the vaccine, as well as its mechanism of action. […] Third, I discuss potential adverse effects, clarifying that mild symptoms following vaccination are a natural result of stimulating the immune system. […] Visual aids can be particularly helpful in explaining why adverse effects occur and reinforcing that this is part of the body’s natural response to the vaccine, further emphasizing the value of vaccination.

• #34 RSV Vaccine Is Recommended for Long-Term Care Facility Residents

  https://www.pulmonologyadvisor.com/news/rsv-vaccine-is-recommended-for-long-term-care-facility-residents/

  The average annual incidence of respiratory syncytial virus-associated hospitalization among adults aged 65 years and older who were community-dwelling, skilled nursing facility, and assisted living residents was 117, 440, and 740 per 100,000 persons, respectively. […] Researchers conducted a 3-year prospective, active surveillance study to compare population-based incidence of RSV-associated hospitalization for community-dwelling adults and residents of skilled nursing and assisted living facilities. […] Further study is needed to assess if our findings will be replicated in other geographic locations, but these data suggest a need for strong vaccine recommendations to prevent RSV disease in this vulnerable population. […] Further study is needed to assess if our findings will be replicated in other geographic locations, but these data suggest a need for strong vaccine recommendations to prevent RSV disease in this vulnerable population, the researchers wrote.

• #35 CDC Issues New Guidance on RSV Vaccines for Older Adults, Nursing Homes – Skilled Nursing News

  https://skillednursingnews.com/2024/06/cdc-issues-new-guidance-on-rsv-vaccines-for-older-adults-nursing-homes/

  In anticipation of the fall flu season, the Centers for Disease Control and Prevention (CDC) is revising its guidelines for the RSV vaccine and recommending that older adults in nursing homes receive the vaccine. […] The recommendations issued Wednesday, strongly advises that adults aged 75 and older adults receive the RSV vaccine. Meanwhile, adults aged 60 to 74 years, who are at heightened risk of severe RSV due to chronic medical conditions like lung or heart disease, particularly nursing home residents, should also get vaccinated, the CDC said. […] RSV infections have had severe outcomes for vulnerable populations such as those in nursing homes.

• #36 RSV Vaccines Effective in Older Adults in Long-Term Care Facilities

  https://www.ajmc.com/view/rsv-vaccines-effective-in-older-adults-in-long-term-care-facilities

  A robust antibody response was found in patients in residents of long-term care facilities who were given the respiratory syncytial virus (RSV) vaccine. […] Use of the vaccine targeted at respiratory syncytial virus (RSV) is recommended for high-risk populations after a new study published in JAMDA found that a robust antibody response was found when adults living in long-term care facilities (LTCF) were given an RSV vaccine. […] The trials that were the basis of the approval of these vaccines focused primarily on healthy older adults, which could have overlooked the ways that the vaccines could affect less healthy older adults living in LTCFs. […] All participants received either the Pfizer or GSK RSV vaccine as part of their routine care. […] Participants were included if they were 60 years or older, were living in an LTCF or living independently in the community, had a life expectancy of more than 6 months, were planning to receive the vaccine, and could provide consent.

• #37 Low RSV Vaccination Rates in Nursing Homes Highlight Urgent Need for Uptake

  https://www.ajmc.com/view/low-rsv-vaccination-rates-in-nursing-homes-highlight-urgent-need-for-uptake

  Nursing home residents face high risks from respiratory viruses, yet vaccination rates for RSV, influenza, and COVID-19 are low for the 20242025 season. […] Only 17.9% of residents received the RSV vaccine, 58.4% received the influenza vaccine, and 29.7% received the COVID-19 vaccine, with regional variations. […] Despite existing programs, more efforts are needed to address barriers and improve vaccination rates among nursing home residents. […] Most nursing home residents have not been afforded the protection offered by vaccination against severe COVID-19, influenza, and RSV disease during the 20242025 respiratory virus season, wrote the investigators of the report. Addressing low coverage of vaccination against COVID-19, influenza, and RSV must be prioritized, and larger facilities and those in counties with high social vulnerability could benefit from effective interventions.

• #38 Low RSV Vaccination Rates in Nursing Homes Highlight Urgent Need for Uptake

  https://www.ajmc.com/view/low-rsv-vaccination-rates-in-nursing-homes-highlight-urgent-need-for-uptake

  Current CDC guidelines recommend a single dose of the RSV vaccine for all adults aged 75 years and older, and adults aged 60 to 74 years at increased risk for severe RSV. […] Despite these limitations, these findings underscore the urgent need to boost vaccination efforts to safeguard one of the most vulnerable populations from preventable respiratory illnesses. […] Although CDC and other federal agencies have programs in place to address both the financial and vaccine hesitancyrelated barriers to vaccination in nursing homes, more needs to be done at every level to protect nursing home residents, who constitute one of the population groups at highest risk for severe respiratory disease, wrote the investigators.

• #39 RSV Vaccination in LTC | CCO

  https://clinicaloptions.com/activities/infectious-disease/rsv-vaccination-in-ltc/67132/content

  Raising awareness and providing education about the RSV vaccine are crucial for increasing vaccine uptake, particularly among long-term care staff, residents, and their families […] Explaining RSV vaccine safety, efficacy, and common adverse effects using clear, engaging visuals helps older adults understand the vaccine and increases their willingness to get vaccinated. […] The importance of respiratory syncytial virus (RSV) vaccines in long-term care settings is defined by 2 key factors: the patient population and the environment. […] Vaccinating vulnerable, older adults is highly important in order to prevent serious illness, hospitalization, and death from respiratory infections. […] The likelihood of more severe cases increases when a greater number of residents contract the infection, highlighting the importance of having a vaccine available to protect residents from serious illness and death.

• #40 Respiratory syncytial virus (RSV) immunisation

  https://www.health.vic.gov.au/immunisation/respiratory-syncytial-virus-immunisation

  Immunisation providers must store and handle all vaccines according to the National Vaccine Storage Guidelines Strive for 5. […] It is mandatory to report all NIP immunisations, including Abrysvo to the AIR. Additionally, providers are strongly encouraged to record all Beyfortus (nirsevimab) immunisations given on the AIR.

• #41 RSV – AWHONN

  https://www.awhonn.org/resources-and-information/rsv/

  Of note, if you have unused maternal RSV vaccine after January 31, clinicians should: Continue to store the vaccine in the refrigerator between 2°C to 8°C (36°F to 46°F). Unopened, refrigerated shelf life for Pfizer’s Abrysvo vaccine is 36 months. […] Regularly monitor the vaccine’s expiration date. Discard any expired vaccine. Any vaccine that is not expired may be used for the 2025-26 respiratory virus season.

• #42

  https://www.gov.uk/government/publications/respiratory-syncytial-virus-rsv-programme-information-for-healthcare-professionals/rsv-vaccination-of-older-adults-information-for-healthcare-practioners

  The individual or their carer should be informed about the risk of haematoma from the injection. […] Vaccination offers the best protection against RSV infection. […] When providing advice to government, the JCVI reviews the current evidence with regard to benefit and cost-effectiveness. […] If RSV vaccine has been inadvertently administered or purposefully prescribed for a young child this should be managed as a Serious Untoward Incident (SUI) and an appropriate investigation carried out. […] Healthcare practitioners should report all inadvertent vaccine administration errors via their local governance systems so that appropriate action can be taken, lessons can be learnt, and the risk of future errors minimised.

• #43 Should You Get an RSV Vaccine? > News > Yale Medicine

  https://www.yalemedicine.org/news/should-you-get-an-rsv-vaccine

  The CDC says most infants will need protection from one of the new RSV immunizationseither the monoclonal antibody or the vaccine. […] ABRYSVO has been shown to reduce the risk of RSV hospitalization for babies by 57% in the first six months after birth, according the CDC. […] Both doctors say the benefits of the new vaccines for older adults outweigh the potential harms in cases where RSV could be life-threatening. They recommend them to all eligible older adults, particularly those with underlying health conditions, such as heart or lung disease, or weakened immune systems.

• #44 Respiratory syncytial virus (RSV) FAQs | NCIRS

  https://ncirs.org.au/ncirs-fact-sheets-faqs-and-other-resources/respiratory-syncytial-virus-rsv-frequently-asked

  Clinical trials for Abyrsvo have shown that use of the Abrysvo vaccine in pregnant women provided infants with good protection from severe RSV; the risk of hospitalisation from RSV infection was reduced by around 60% in infants during their first 6 months of life. […] Data on the effectiveness of RSV immunisation products come from clinical trials. Real-world effectiveness studies are currently underway in countries where these products have been in use since late 2023.

• #45 RSV Vaccine Is Recommended for Long-Term Care Facility Residents

  https://www.infectiousdiseaseadvisor.com/news/rsv-vaccine-is-recommended-for-long-term-care-facility-residents/

  The average annual incidence of severe respiratory syncytial virus (RSV) was higher among residents of skilled nursing and assisted living facilities vs community-dwelling adults, according to study results published in The Journal of Infectious Diseases. […] Further study is needed to assess if our findings will be replicated in other geographic locations, but these data suggest a need for strong vaccine recommendations to prevent RSV disease in this vulnerable population. […] Further study is needed to assess if our findings will be replicated in other geographic locations, but these data suggest a need for strong vaccine recommendations to prevent RSV disease in this vulnerable population, the researchers wrote.

• #46 Vaccination for Respiratory Syncytial Virus: A Narrative Review and Primer for Clinicians

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10747850/

  Pregnant individuals can receive the maternal RSVpreF vaccine concurrently with other recommended vaccines, including tetanus, diphtheria, and pertussis (Tdap), influenza, and COVID-19 vaccines. […] In contrast to infants, direct immunization of older adults is available, given that most adults would have been infected by RSV previously in their childhood or early adulthood. Two vaccines are currently available for adults aged 60 years and above: a non-adjuvanted bivalent vaccine (AbrysvoTM, Pfizer Inc., which is the same one used for maternal vaccination) and an adjuvanted non-bivalent vaccine (ArexvyTM, GSK Inc., London, UK). […] This review underscores the significant impact of RSV on global health, particularly in infants, young children, and older adults. It highlights the importance of timely diagnosis, supportive care, potential antiviral treatments, and vaccination for reducing the health burden of RSV infection. Maternal vaccination for infant protection and vaccination in older adults are now available, with ongoing efforts to extend vaccination to younger at-risk populations and to seronegative children. For RSV vaccination to be implemented successfully, global guidelines and national policies need to recommend RSV vaccination, and health systems need to ensure the affordability and accessibility of RSV vaccines, especially in low- and middle-income countries. Finally, more trial data and post-marketing surveillance of RSV vaccines will help build confidence in the long-term efficacy and safety of RSV vaccination.

Zobacz więcej